Skip to main content

Dan German Blazer III

Professor of Surgery
Surgical Oncology
Box 3247 Med Ctr, Durham, NC 27710
485 Seeley G.Mudd Bldg., Searle Center, Durham, NC 27710

Current Appointments & Affiliations


Professor of Surgery · 2023 - Present Surgical Oncology, Surgery
Interim Chief of Surgical Oncology · 2025 - Present Surgical Oncology, Surgery
Member of the Duke Cancer Institute · 2008 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published May 17, 2016
Going to church could help you live longer, study says
Published June 17, 2013
Duke doctor duo share same name, ethics

View All News

Recent Publications


Management of Desmoid Tumors.

Journal Article Curr Oncol Rep · October 11, 2025 PURPOSE OF REVIEW: This review highlights the evolving management of desmoid tumors, including the importance of an accurate diagnosis, the potential role for surgery and radiation therapy in select cases, growing data supporting the use of radiology-guide ... Full text Link to item Cite

Social Vulnerability as a Neighborhood-Level Determinant of Pancreatic Cancer Survivorship: A National Analysis of Veterans Affairs Patients.

Conference Ann Surg Oncol · September 2, 2025 BACKGROUND: Veterans Affairs (VA) patients participate within the largest USA equal-access healthcare system, though still experience cancer mortality disparities by social determinants. The Social Vulnerability Index (SVI)-measuring community poverty, min ... Full text Link to item Cite

Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases.

Journal Article Cancer · July 1, 2025 BACKGROUND: Gastric cancer with synchronous peritoneal metastases is a debilitating disease with limited treatment options. This article describes an update of the 2018 Chicago Consensus guidelines addressing the management of gastric cancer with synchrono ... Full text Link to item Cite
View All Publications

Recent Grants


Clinical Trials Umbrella - Scanned Beam

Clinical TrialPrincipal Investigator · Awarded by Massachusetts General Hospital · 2019 - 2025

A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO)

Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2019 - 2025

View All Grants

Education, Training & Certifications


Duke University · 1999 M.D.